DDSS Labopharm Inc. featured news, full reports, and detailed charts
Labopharm Inc. (DDSS) Wrap Up:
No business description found.www.labopharm.com
Founded in 1990
Labopharm Inc (DDSS:NASDAQ)
LAST $1.41 USD
CHANGE TODAY +0.01 0.71%
VOLUME 259.7K
As of 3:59 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Labopharm Inc (DDSS)
|
OPEN
$1.40
|
PREVIOUS CLOSE
$1.40
|
|
|
DAY HIGH
$1.44
|
DAY LOW
$1.37
|
|
|
52 WEEK HIGH
07/6/09 - $2.95
|
52 WEEK LOW
12/4/08 - $0.32
|
|
|
MARKET CAP
81.0M
|
AVERAGE VOLUME 3 mo
341.1K
|
|
|
DILUTED EPS TTM
$-0.51
|
SHARES OUTSTANDING
57.4M
|
|
|
DDSS Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
DDSS Top Compensated Officers
Mr. James R. Howard-Tripp
Chief Executive Officer, President, Director,...
Total Annual Compensation: C$520.2K
Mr. Mark A. D'Souza
Chief Financial Officer and Senior Vice Presi...
Age: 48
Total Annual Compensation: C$310.6K
Ms. Mary Anne Heino
President of Labopharm USA Inc.
Total Annual Compensation: C$331.1K
Dr. Damon C. Smith BSc, Ph.D.
Senior Vice President of Research & Developme...
Total Annual Compensation: C$306.3K
Mr. Tony Playle
Managing Director of Labopharm Europe Limited
Total Annual Compensation: C$142.6K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for Labopharm Inc (DDSS)
Labopharm Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2009
11/6/2009
Labopharm Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported total revenue was CAD 6.6 million compared with CAD 9.4 million for the third quarter of fiscal 2008. Net loss was CAD 6.9 million, or CAD 0.12 per share, compared with CAD 6.0 million, or CAD 0.11 per share, for the third quarter of fiscal 2008. Loss before income taxes was CAD 6.89 million compared to CAD 5.32 million for the same period a year ago. Cash used in operating activities was CAD 5.69 million compared to CAD 10.58 million for the same period a year ago. Amount spent on acquisition of property, plant and equipment was CAD 0.25 million compared to CAD 0.19 million for the same period a year ago. For the nine months, the company reported revenue was CAD 17.9 million compared with CAD 17.6 million for the first nine months of fiscal 2008. Net loss was CAD 19.8 million, or CAD 0.35 per share, compared with CAD 26.0 million, or CAD 0.46 per share, for the first nine months of fiscal 2008. Loss before income taxes was CAD 19.74 million compared to CAD 24.51 million for the same period a year ago. Cash used in operating activities was CAD 19.25 million compared to CAD 26.66 million for the same period a year ago. Amount spent on acquisition of property, plant and equipment was CAD 0.32 million compared to CAD 1.34 million for the same period a year ago.
Labopharm Inc., Q3 2009 Earnings Call, Nov-06-2009
10/29/2009
Labopharm Inc., Q3 2009 Earnings Call, Nov-06 2009
Labopharm 's Trazodone API Supplier Resolves Outstanding Manufacturing Issues with the FDA
10/7/2009
Labopharm Inc. announced that it has been informed by Angelii, the manufacturer of the active pharmaceutical ingredient (API) for the company’s novel trazodone formulation, that it has received a letter from the U.S. Food and Drug Administration (FDA) stating that Angelini has appropriately addressed all deficiencies cited by the FDA following its inspection of the manufacturing facility in June and July of this year. The letter further states that Angelini’s manufacturing facility has been classified as acceptable. Labopharm received a complete response letter from the FDA on July 17, 2009 indicating the company's new drug application (NDA) for its novel trazodone formulation could not be approved in its present form due to the deficiencies at the API supplier’s manufacturing facility. The letter did not raise any efficacy or safety issues.
DDSS Competitors
| Company | Last | Change |
| Cipher Pharmaceuticals Inc | C$0.46 CAD | 0.00 |
| Flamel Technologies SA | $7.48 USD | +0.12 |
| Intelgenx Technologies Corp | C$0.64 CAD | 0.00 |
| Penwest Pharmaceuticals Co | $2.28 USD | +0.01 |
| SCOLR Pharma, Inc | $0.61 USD | -0.11 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | DDSS | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 3.9x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 1.6x |
|
|
DDSS |
||
|
DDSS transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About Labopharm Inc.
More news for DDSS
Labopharm to present data on its novel trazodone formulation at three upcoming international medical meetings
LAVAL, QC, Sept. 9 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS - News; NASDAQ: DDSS - News) today announced that three separate posters will be presented at three upcoming internationally prestigious medical meetings showcasing data on its novel trazodone formulation. Two posters will be presented in mid-September, including:The poster entitled: Modeling and Simulation to Optimize Efficacy and Tolerability for a Once-a-day Trazodone Formulation at the 22nd European College of Neuropsychopharmacology Congress to be held from September 12 to 16, 2009 in Istanbul, Turkey; and,The poster entitled: Once-daily Trazodone: Overview of Pharmacokinetic Properties, which will be presented at the 2009 American College of Clinical Pharmacology (ACCP) 38th Annual Meeting in San Antonio, Texas from September 13-15, 2009.In October, during the 61st Institute on Psychiatric Services meeting to be held from October 8 to 11th, 2009 in New York City the poster entitled: A Novel Contramid®-based Reformulation of Trazodone in Major Depressive Disorder: Characteristics of Antidepressant Response will be presented.Complete copies of the three poster presentations will...Click here to read the whole Article (external link)
Labopharm receives notice of ANDA submission with paragraph IV certification for generic of Ryzolt(TM)
LAVAL, QC, Sept. 30 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS - News; NASDAQ: DDSS - News) today announced it has received notice from Sun Pharma Global FZE advising that Sun has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for approval to market 100, 200 and 300 mg generic versions of Ryzolt(TM) (tramadol hydrochloride extended-release 100, 200 and 300 mg tablets) in the United States. Under the Drug Price Competition and Patent Term Restoration Act (known as the Hatch-Waxman Act), Ryzolt has a new dosage form market exclusivity period that prevents final approval of Sun's ANDA until the exclusivity period expires on December 31, 2011.Sun's ANDA includes a paragraph IV certification to obtain approval to manufacture, use, or sell its generic versions before the expiration of Patent Nos. 5,591,452, 6,254,887 and 6,607,748. U.S. Patent Nos. 5,591,452 and 6,254,887, which are owned by Purdue Pharma Products L.P., Labopharm's marketing and distribution partner in the US, expire in May 2014. U.S. Patent # 6,607,748, which is owned by Labopharm, expires in June 2020. All three patents are listed in the FDA's Approved Drug Products with Therapeut...Click here to read the whole Article (external link)
Labopharm completes distribution and supply agreement with Grunenthal for twice-daily tramadol-acetaminophen for a number of European countries
- The Agreement Includes Up-Front and Milestone Payments of up to 7.5 Million Euros - LAVAL, QC, Oct. 8 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS - News; NASDAQ: DDSS - News) today announced that its wholly owned subsidiary, Labopharm Europe Limited, has completed a distribution and supply agreement with Grunenthal GmbH for its twice-daily tramadol acetaminophen formulation for a number of countries in Europe.Under the terms of the agreement, Grunenthal has the exclusive right to market and sell Labopharm's twice-daily tramadol-acetaminophen formulation in a number of European countries. Labopharm will supply Grunenthal with unpackaged tablets and will receive a fixed transfer price inclusive of gross margin.Labopharm will receive 3.5 million Euros on signature and up to 4 million Euros in milestone payments upon achievement of certain regulatory and product reimbursement approvals prior to the launch of the product."We are pleased to have established the first marketing partnership for our twice-daily tramadol-acetaminophen formulation," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "This agreement represents the initial step in the...Click here to read the whole Article (external link)
Labopharm announces that its trazodone API supplier has resolved outstanding manufacturing issues with the FDA
LAVAL, QC, Oct. 7 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS - News; NASDAQ: DDSS - News) today announced that it has been informed by Angelini, the manufacturer of the active pharmaceutical ingredient (API) for the Company's novel trazodone formulation, that it has received a letter from the U.S. Food and Drug Administration (FDA) stating that Angelini has appropriately addressed all deficiencies cited by the FDA following its inspection of the manufacturing facility in June and July of this year. The letter further states that Angelini's manufacturing facility has been classified as acceptable. Labopharm received a complete response letter from the FDA on July 17, 2009 indicating the Company's new drug application (NDA) for its novel trazodone formulation could not be approved in its present form due to the deficiencies at the API supplier's manufacturing facility. The letter did not raise any efficacy or safety issues.Labopharm's novel formulation of trazodone is currently under regulatory review in the U.S. with an action date under the Prescription Drug Users Fee Act (PDUFA) of February 11, 2010.About Labopharm Inc.Labopharm is an emerging leader in optimizing the performance ...Click here to read the whole Article (external link)
Midday Movers: Pump Up the Volume
Stock quotes in this article: DDSS , TIV , ASTC , ...Click here to read the whole Article (external link)
Early Movers: Pump Up the Volume
Stock quotes in this article: DDSS , TIV , ASTC , ...Click here to read the whole Article (external link)
Labopharm to host conference call Friday, November 6, 2009 at 10:00 a.m. (ET)
- Management to discuss third quarter financial results - LAVAL, QC, Oct. 29 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS - News; NASDAQ: DDSS - News) today announced that it will host a conference call on Friday, November 6, 2009 at 10:00 a.m. (ET) to discuss its third quarter 2009 financial results. Labopharm will report its third quarter 2009 financial results via news release before the markets open the same day.To access the conference call by telephone, dial 416-644-3422 or 1-877-974-0448. Please connect approximately 15 minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Friday, November 13, 2009 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 4171872 followed by the number sign.A live audio webcast of the conference call will be available at www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time ...Click here to read the whole Article (external link)
Labopharm Reports Results for Third Quarter Fiscal 2009
- Company Advances Plans to Realize the Benefits of Commercialization: Streamlines Operations to Focus on Nearer-Term Commercial Opportunities - LAVAL, QC, Nov. 6 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS - News; NASDAQ: DDSS - News) today reported its financial results for the third quarter ended September 30, 2009. All figures are in Canadian dollars unless otherwise stated."We have made strong progress in recent months towards the commercialization of our novel trazodone formulation in both the United States and Canada," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "In the U.S., with the matters raised in the Food and Drug Administration (FDA)'s complete response letter now resolved, we await the Agency's decision regarding approval of our formulation and continue to prepare for commercialization in the first half of 2010 pending such approval. In Canada, our new drug submission (NDS) has been accepted for review by Health Canada and we look forward to its response during the third quarter of next year."Financial SummaryRevenue from sales of the Company's once-daily tramadol product for the third quarter of fiscal 2009 increased ...Click here to read the whole Article (external link)
Would you like to leave a comment about Labopharm Inc. DDSS
Find out what social network information about Labopharm Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Labopharm Inc. there is more great information available at Realpennies.com